Moreover, another study that subdivided the patient group into pre-AD and full-AD based on an MMSE evaluation of the disease’s progression found that BACE1-AS plasma levels were lower in pre-AD individuals than those of the full-AD patients and healthy subjects, strengthening its potency as a predictive biomarker [99]. This evidence concerns the gene BACE1 and Alzheimer disease.